首页> 美国卫生研究院文献>The Journal of Biological Chemistry >SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1
【2h】

SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1

机译:泛素连接酶偶像酶的平均值降低了LDL受体水平并通过SENP1逆转

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inducible degrader of the low-density lipoprotein receptor (IDOL) is an E3 ubiquitin ligase mediating degradation of low-density lipoprotein (LDL) receptor (LDLR). IDOL also controls its own stability through autoubiquitination, primarily at lysine 293. Whether IDOL may undergo other forms of posttranslational modification is unknown. In this study, we show that IDOL can be modified by small ubiquitin-like modifier 1 at the K293 residue at least. The SUMOylation of IDOL counteracts its ubiquitination and augments IDOL protein levels. SUMOylation and the associated increase of IDOL protein are effectively reversed by SUMO-specific peptidase 1 (SENP1) in an activity-dependent manner. We further demonstrate that SENP1 affects LDLR protein levels by modulating IDOL. Overexpression of SENP1 increases LDLR protein levels and enhances LDL uptake in cultured cells. On the contrary, loss of SENP1 lowers LDLR levels in an IDOL-dependent manner and reduces LDL endocytosis. Collectively, our results reveal SUMOylation as a new regulatory posttranslational modification of IDOL and suggest that SENP1 positively regulates the LDLR pathway via deSUMOylation of IDOL and may therefore be exploited for the treatment of cardiovascular disease.
机译:低密度脂蛋白受体(偶像)的诱导降解剂是E3泛素连接酶介导的低密度脂蛋白(LDL)受体(LDLR)的降解。偶像还通过自动吸收来控制自己的稳定性,主要是在赖氨酸293。偶像是否可能经历其他形式的后期改性。在这项研究中,我们表明,偶像蛋白类似于K293残基的小泛素样改性剂1可以通过偶像蛋白样改性剂1进行修饰。偶像酚的平等抵消其泛素化并增强偶像蛋白水平。 Sumo特异性肽酶1(SENP1)以活性依赖性方式有效地反转偶像和偶像蛋白的相关增加。我们进一步证明SENP1通过调节偶像来影响LDLR蛋白水平。 SeNP1的过度表达增加了LDLR蛋白水平并增强培养细胞中的LDL摄取。相反,SeNP1的丧失以偶像依赖性的方式降低了LDLR水平并降低了LDL内吞作用。统称,我们的结果将Suflation揭示为偶像的新监管后改性,并表明SENP1通过偶像脱醇的脱索积极调节LDLR途径,因此可以剥削用于治疗心血管疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号